(Q46848758)

25 December 2017

title

Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment (English)

1 reference

25 December 2017

1 reference

1 reference

3

1 reference

25 December 2017

Paul Emery

8

object named as

P Emery

0 references

Maya Hema Buch

4

object named as

M H Buch

1 reference

25 December 2017

E M Vital

1

1 reference

25 December 2017

S Dass

2

1 reference

25 December 2017

V Goëb

5

1 reference

25 December 2017

K Henshaw

6

1 reference

25 December 2017

F Ponchel

7

1 reference

25 December 2017

publication date

1 May 2010

1 reference

25 December 2017

published in

Arthritis & Rheumatology

1 reference

25 December 2017

volume

62

1 reference

25 December 2017

issue

5

1 reference

25 December 2017

page(s)

1273-1279

1 reference

25 December 2017

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

cites work

1 reference

Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati

21 January 2018

1 reference

Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis

21 January 2018

1 reference

Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response

21 January 2018

1 reference

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

21 January 2018

1 reference

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

21 January 2018

1 reference

Competence and competition: the challenge of becoming a long-lived plasma cell

21 January 2018

1 reference

The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.

21 January 2018

1 reference

Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients

21 January 2018

1 reference

Consensus statement on the use of rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/ART.27359

1 reference

25 December 2017

Dimensions Publication ID

1028551460

0 references

1 reference

25 December 2017